Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833883 · ClinicalTrials.gov registry record · Phase 1
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02833883: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02833883 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02833883, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The main purpose of this study to define the good and/or bad effects of the combination of enzalutamide and CC-115 in patients with castration-resistant prostate cancer.
Interventions
- DRUG Enzalutamide
- DRUG CC-115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-07 |
| Est. Completion | 2023-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02833883
The ClinicalTrials.gov registry entry for NCT02833883 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02833883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02833883 about?
NCT02833883 is a clinical study titled "Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer". The main purpose of this study to define the good and/or bad effects of the combination of enzalutamide and CC-115 in patients with castration-resistant prostate cancer.
What is the current status of trial NCT02833883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-07. Estimated completion is 2023-01-13.
What interventions are being tested in trial NCT02833883?
The interventions under investigation include: Enzalutamide (DRUG), CC-115 (DRUG).
Who is sponsoring clinical trial NCT02833883?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.